Equity Analysts at Numis Reconfirmed their “Buy” rating for Diurnal Group Plc (LON:DNL). The Price Target is Set to GBX 185.00; Cytrx Has 0.73 Sentiment

CytRx Corporation operates as a biopharmaceutical research and development firm specializing in oncology. The company has market cap of $46.71 million. The companyÂ’s product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It currently has negative earnings. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors.

In an analyst note issued to clients and investors on Tuesday, 13 February, Diurnal Group Plc (LON:DNL) stock “Buy” was maintained by Analysts at Numis. They currently have a GBX 185.00 target price per share on the stock. Numis’s target price per share would indicate a potential upside of 6.02% from the company’s current price.

The stock increased 2.02% or GBX 3.5 during the last trading session, reaching GBX 177. About 562 shares traded. Diurnal Group plc (LON:DNL) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Diurnal Limited operates as a specialty pharmaceutical company. The company has market cap of 93.07 million GBP. It develops hormone therapeutics for the treatment of rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. It currently has negative earnings. The Company’s product pipeline include Infacort for use in children suffering from adrenal insufficiency; and Chronocort that is in Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients.

Among 3 analysts covering Diurnal Group Plc (LON:DNL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Diurnal Group Plc has GBX 208 highest and GBX 169 lowest target. GBX 190.33’s average target is 7.53% above currents GBX 177 stock price. Diurnal Group Plc had 15 analyst reports since February 4, 2016 according to SRatingsIntel. As per Wednesday, September 6, the company rating was maintained by Numis Securities. Numis Securities maintained it with “Buy” rating and GBX 184 target in Wednesday, March 30 report. The firm has “Buy” rating given on Monday, July 11 by Numis Securities. The firm has “Buy” rating by Numis Securities given on Wednesday, January 25. The stock has “Buy” rating by Numis Securities on Wednesday, December 21. Numis Securities maintained Diurnal Group plc (LON:DNL) on Monday, March 20 with “Buy” rating. Numis Securities maintained Diurnal Group plc (LON:DNL) rating on Monday, November 21. Numis Securities has “Buy” rating and GBX 187 target. On Thursday, March 2 the stock rating was maintained by Numis Securities with “Buy”. The stock of Diurnal Group plc (LON:DNL) earned “Buy” rating by Numis Securities on Monday, February 29. Panmure Gordon maintained Diurnal Group plc (LON:DNL) rating on Thursday, June 15. Panmure Gordon has “Buy” rating and GBX 178 target.

The stock increased 1.81% or $0.03 during the last trading session, reaching $1.69. About 200,838 shares traded. CytRx Corporation (CYTR) has declined 78.08% since February 13, 2017 and is downtrending. It has underperformed by 94.78% the S&P500.

Pekin Singer Strauss Asset Management Il holds 0.01% of its portfolio in CytRx Corporation for 67,555 shares. Bank Of America Corp De owns 2,144 shares or 0% of their US portfolio. Moreover, Bank Of Montreal Can has 0% invested in the company for 490 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Barclays Plc, a United Kingdom-based fund reported 9 shares.